These results come in the context of dramatic reports showing that new HER2-targeted antibody–drug conjugates are highly effective in a large percentage of breast tumors traditionally classified as HER2-negative (score 1 +) [43, 44]. This evidence concerns the gene ERBB2 and breast neoplasm.